Læknaneminn - 01.04.2018, Blaðsíða 27

R
itr
ýn
t e
fn
i
27
Heimildaskrá

1. Hughes RAC, Cornblath DR. Guillain­Barré syndrome. The Lancet.
2005;366(9497):1653­1666.
2. Guillain B, Strohl. Sur un syndrome de radiculo­nevrite avec
hyperalbuminose du liquide cephalorachidien sans reaction cellulaire.
Remarques sur les caracteres cliniques et graphiques des refl exes
tendineux. Bull Soc Med Hop Paris. 1916;28:1462­1470.
3. Dimachkie MM, Barohn RJ. Guillain­Barre syndrome and variants.
Neurol Clin. 2013;31(2):491­510.
4. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis,
and treatment of Guillain­Barré syndrome. The Lancet Neurology.
2008;7(10):939­950.
5. Eldar AH, Chapman J. Guillain Barre syndrome and other immune
mediated neuropathies: diagnosis and classification. Autoimmun Rev.
2014;13(4­5):525­530.
6. Meulstee vdM. Electrodiagnostic criteria for polyneuropathy and
demyelination. application in 135 patients with Guillain Barré
syndrome. Journal of Neurology. 1995(27):21­24.
7. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA,
Jacobs BC. Diagnosis of Guillain­Barre syndrome and validation of
Brighton criteria. Brain. 2014;137(Pt 1):33­43.
8. Fisher M. An Unusual Variant of Acute Idiopathic Polyneuritis
(Syndrome of Ophthalmoplegia, Ataxia and Areflexia). The New
England Journal of Medicine. 1956;255(2):57­65.
9. Kuwabara S, Yuki N. Axonal Guillain­Barré syndrome: concepts and
controversies. The Lancet Neurology. 2013;12(12):1180­1188
10. Hadden C, Hughes, Zielasek, Hartung, Toyka, Swan.
Electrophysiological classification of Guillain­Barré syndrome.
Clinical Associations and Outcome. Annals of neurology. 1998.
11. Kuwabara O, Misawa. Does Campylobacter jejuni infection
elicit “demyelinating” Guillain–Barré syndrome? Neurology.
2004;63(3):529­533.
12. Mishu B. Role of infection due to Campylobacter jejuni in the
initiation of Guillain­Barré syndrome. Clinical infectious diseases.
1993;17(1):104­108.
13. Gurwood D. Guillain Barré syndrome. Optometry. 2006;77(11):540­
546.
14. van Doorn PA. Diagnosis, treatment and prognosis of Guillain­
Barre syndrome (GBS). Presse Med. 2013;42(6 Pt 2):e193­201.
15. Meché vD. Guillain­Barré syndrome and chronic inflammatory
demyelinating polyneuropathy: immune mechanisms and update on
current therapies. Annals of neurology. 1995;37(1):14­31.
16. Hughes E, Wijdicks. Supportive Care for Patients With Guillain­
Barré Syndrome. Archives of Neurology. 2005;62(8):1194­1198.
17. Group GBSST. Double­blind trial of intravenous
methylprednisolone in Guillain­Barré syndrome. The Lancet.
1993;341(8845):586­590.
18. Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld
R, van Doorn PA. Immunotherapy for Guillain­Barre syndrome: a
systematic review. Brain. 2007;130(Pt 9):2245­2257.
Blóðþrýstingsmælar | Lífsmarkamælar | Augn- og eyrnaskoðunartæki
Laryngoscope (barkaspegill) | Hlustunarpípur (stethoscope) | Hitamælar
Reflexhamrar | Tónkvíslir | Ljós
Verið velkomin í verslun okkar
Opið virka daga kl. 8:30–17:00
Síðumúli 16 I 108 Reykjavík I Sími 580 3900 I fastus.is
fastus.is
HAGKVÆM OG VÖNDUÐ
LÆKNINGATÆKI
10%
AFSLÁTTUR
AF RIESTER VÖRUM
TIL HÁSKÓLANEMA